All News

October 31, 2024

AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies

Expanded agreement includes development of additional transgenic mouse technologies and performance of additional therapeutic antibody research programs Foster City, Calif. – October 31, 2024 – AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the expansion of a previous agreement with Gilead Sciences, Inc. (Nasdaq: GILD) […]

July 17, 2024

AbTherx Appoints Pallavi Tawde, PhD, as Head of Preclinical R&D Strategy

Former Pfizer, BMS, and Denali scientific leader to lead expansion of antibody discovery, preclinical development, and early clinical capabilities Foster City, Calif. – July 17, 2024 – AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the appointment of Pallavi Tawde, PhD, to the newly created […]

June 18, 2024

AbTherx Opens Antibody Discovery Technologies Research Center

New research center’s world-class antibody discovery capabilities support a growing portfolio of Atlas™ Mice transgenic technologies and partnerships Foster City, Calif. – June 18, 2024 – AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the opening of its new antibody discovery technologies research center. The new state-of-the-art […]

May 9, 2024

The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery

Bar Harbor, Maine and Mountain View, California – May 9, 2024 – The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and derisk the development of vital new therapies. This collaboration will include co-development […]

March 20, 2024

AbTherx Appoints Jessica Stark, PhD, as Scientific Advisor

Glycoimmunology expert and co-inventor of AbLec technology joins AbTherx to expand expertise around challenging drug targets Mountain View, Calif. – March 20, 2024 – AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Jessica Stark, PhD, as a scientific advisor. In her new role, Dr. […]

March 13, 2024

AbTherx Partners with Single Cell Technology for First Antibody Discovery Campaigns

Partnership provides AbTherx and licensees of AbTherx’s Atlas™ Mice access to Single Cell Technology’s proprietary single B cell screening engine Mountain View and San Jose, Calif. – March 13, 2024 – AbTherx, Inc., a biotechnology company with innovative technologies to enable and accelerate antibody discovery, and Single Cell Technology, Inc. (“Single Cell”), a biotechnology company […]

March 7, 2024

AbTherx Appoints Janine Schuurman, PhD, as Scientific Advisor

Antibody expert and co-inventor of DuoBody®, HexaBody®, and HexElect® technologies joins AbTherx to drive expansion of the Atlas™ Mice platform Mountain View, Calif. – March 7, 2024 – AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Janine Schuurman, PhD, as a scientific advisor. In […]

March 4, 2024

AbTherx Announces Transition from Early Access to Commercialization of its Bispecific and Full Human Diversity Antibody Discovery Technologies

Atlas™ Mice can now be evaluated by pharmaceutical and biotech companies and accessed through a network of preferred service providers Mountain View, Calif. – March 4, 2024 – AbTherx, a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced expanded commercialization of its bispecific and full human diversity antibody discovery technologies. […]

November 28, 2023

AbTherx Appoints David Meininger, PhD, MBA as Chief Business Officer

Biopharma executive with proven track record brings substantial strategy, business development, and licensing experience to AbTherx leadership team Mountain View, Calif. – November 28, 2023 – AbTherx, a privately held biotech company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of David Meininger, PhD, MBA to the newly created position […]

August 16, 2023

AbTherx Appoints Gavin Thurston, PhD, as Scientific Advisor

Former Regeneron Oncology Leader Joins AbTherx to Advance its Antibody Discovery Platform Mountain View, Calif. – August 16, 2023 – AbTherx, a privately held biotech company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Gavin Thurston, PhD, as a scientific advisor. In his new role, Dr. Thurston will provide […]

June 7, 2023

AbTherx Launches a Next-Generation Antibody Discovery Platform

The company brings together a proven team and novel technologies to increase efficiencies in antibody discovery Mountain View and San Diego, Calif. – June 7, 2023 – AbTherx, Inc., a privately held biotech company with novel technologies that accelerate antibody discovery, announced the launch of its next-generation human antibody discovery platform. AbTherx’s novel transgenic mouse […]

June 7, 2023

AbTherx Announces License Agreement with Gilead

License from Gilead grants AbTherx worldwide rights to a novel human therapeutic antibody discovery platform Mountain View and San Diego, Calif. – June 7, 2023 – AbTherx, Inc., a privately held biotech company focused on accelerating the discovery and development of antibody therapeutics, today announced a license agreement with Gilead Sciences, Inc. (Nasdaq: GILD). The […]